Back to top
more

Precision BioSciences (DTIL)

(Real Time Quote from BATS)

$9.63 USD

9.63
84,360

+0.03 (0.31%)

Updated Sep 19, 2024 09:42 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 277.6% in Precision BioSciences (DTIL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock

Precision BioSciences (DTIL) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade

The consensus price target hints at a 307.9% upside potential for Precision BioSciences (DTIL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 549.35% and 487.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?

The mean of analysts' price targets for Precision BioSciences (DTIL) points to a 200.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates

Kronos Bio (KRON) delivered earnings and revenue surprises of -16.28% and 68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?

Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know

The consensus price target hints at a 407.9% upside potential for Precision BioSciences (DTIL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?

Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -211.67% and 75.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 3.23% and 24.34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -82.61% and 14.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -46.30% and 93.17%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?

Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CHMP Endorses BioMarin's (BMRN) Voxzogo for Use in Infants

A final decision study on BioMarin's (BMRN) Voxzogo to treat children above four months with achondroplasia is expected before year's end.

CHMP Endorses AstraZeneca's (AZN) Enhertu in Lung Cancer

Data from a mid-stage study shows that treatment with AstraZeneca's (AZN) Enhertu achieved strong and durable tumor responses in certain non-small cell lung cancer patients.

After Plunging -27.45% in 4 Weeks, Here's Why the Trend Might Reverse for Precision BioSciences (DTIL)

The heavy selling pressure might have exhausted for Precision BioSciences (DTIL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Precision BioSciences (DTIL) Reports Q2 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 56.52% and 200.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers Squibb (BMY) Misses Q2 Earnings and Revenue Estimates

Bristol Myers (BMY) delivered earnings and revenue surprises of -12.06% and 4.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -4.55% and 33.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of -20% and 9.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 37.14% and 37.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q3 Earnings Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 76.32% and 12.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?